Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/ Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma

Next Previous
Trial Profile

A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/ Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Carcinoma; Colon cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms AVANT
  • Sponsors Roche

    • Most Recent Events

    • 01 Feb 2020 Results published in the Annals of Oncology
    • 16 Jan 2020 Results (n=6501) of pooled analysis of six clinical trials (NCT00079274; NCT00096278; NCT00004931; NCT00275210; NCT00265811; NCT00112918) examining the change of outcomes over 10-year period in patients with stage 3 colon cancer who were treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database, published in the Annals of Oncology.
    • 14 May 2018 Results (n=3451) assessing the predictive potential of TSR, by determining the effects on DFS and OS in patients with high-risk stage II and stage III colon cancer who received standard oxaliplatin-based chemotherapy with or without addition of bevacizumab, were published in the British Journal of Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top